Integrative genomic and drug sensitivity profiling of High-Risk Chronic Myeloid Leukemia Patients in the Context of Personalized Medicine
Year: 2021
Type: dissertation
Study design: Observational Study
Abstract: Chronic myeloid leukemia (CML) is an adulthood leukemia that accounts for 15% of all leukemia patients. The hallmark of the disease is the BCR-ABL1 fusion gene. The development of Tyrosine kinase inhibitors targeted therapy has led to dramatic improvement in CML management with the life expectancy of CML patients approaching normal rates. Nevertheless, certain challenges in CML management remain unmet. CML progression from the chronic phase (CP) to the blast phase (BP) occurs in 5% of CML patients and is associated with dismal survival. Additionally, a minority of CML patients express p190-BCR-ABL1 isoform, which is associated with inferior treatment responses. Characterization of the mechanisms underlying the pathogenesis of high-risk CML is warranted to enable optimization of the therapeutic approaches for these patients. We aimed to investigate the role of mutations at different phases of CML, and to identify genetic biomarkers that allow better risk assessment and optimization of CML management. Furthermore, we integrated genetic and drug sensitivity profiling to identify effective drugs in a personalized medicine approach. In study I, we applied comprehensive sequencing techniques to a cohort of 59 CML patients, including 19 BP and 40 CP patients. In comparison to CP, BP patients demonstrated higher mutational load and were associated with recurrent mutations involving ABL1, ASXL1, and RUNX1 genes. Fusion genes were also identified as recurrent genetic abnormalities in BP patients. Cancer-associated gene mutations correlated with inferior treatment outcomes in CP patients. Finally, we presented two BP patients who were managed using a personalized approach and achieved good responses, highlighting the potential power of this strategy in BP management. In study II, RUNX1 was selected as an example driver mutation in CML progression. RUNX1 mutations were identified in 35% of patients. We also identified mutagenic AID/RAG axis activity which was specific to RUNX1-mutated patients. RUNX1-mutated BP patients demonstrated the overexpression of lymphoid transcription factors as well as aberrant expression of lymphoid antigens (CD19/CD7). We identified targeted therapies with enhanced sensitivities in RUNX1-mutated blasts. We further used CRISPR/Cas9 gene editing to model RUNX1 mutations in cell lines. Finally, we demonstrated the efficiency of CD19 CAR T-cell immunotherapy in targeting RUNX1-mutated blasts. In study III, we performed genomic and phosphorylation profiling for four p190-CML patients and validated findings in two progenitor cell lines (Ba/f3 and HPC-LSK). We demonstrated novel evidence for the p190-specific activation of IFN/JAK1/STAT1 pathway in CML. Other important signaling pathways included Src and PAK1 signaling. We also identified novel p190-specific drug vulnerabilities. Finally, we validated these findings in a cohort of Ph+ ALL patients. In conclusion, our study provides novel insights into the molecular pathogenesis of high-risk CML patients, including BP-CML and p190-CML patients. We identified potential biomarkers, which can be involved in the risk-assessment of CML. Integration of genetic and drug screening data enabled the identification of promising drug candidates. Taken together, we highlighted the potential value of the personalized medicine approach for optimizing the management of high-risk CML patients.
Author: Shady Adnan Awad
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W3184654964
